Hims & Hers Health, Inc. (HIMS) Surpasses Market Returns: Some Facts Worth Knowing
The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $29.55, representing a +1.41% change from its previous close.
Is Hims & Hers Stock Too Cheap to Pass Up?
Hims & Hers (HIMS -8.84%) has seen incredibly high growth, but the market is skeptical that will continue. In this video, Travis Hoium shows just how cheap the stock is today.
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?
What goes up can come down. Investors who jumped on the Hims & Hers Health (HIMS -4.12%) bandwagon have experienced this pain first-hand.
Here's why Hims & Hers stock price has crashed: buy the dip?
Hims & Hers stock price has imploded this year, erasing some of the gains made in 2024 when it became one of the top-performing companies in the US. HIMS has crashed to $33.35, down by over 54% from its highest point this year.
Hims & Hers Health: Reaching Escape Velocity Goes Unnoticed By The Market
I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS' stock drop, in my view. 2025 revenue guidance of $2.29-$2.39 billion and a 3.6x multiple on its $8.3 billion market cap suggest undervaluation. HIMS' PEG ratio of ~1 (P/E of 58 ÷ 56% growth) signals undervaluation for a high-growth company, typically seen in mature firms, not one scaling at 50%+ with 85% customer.
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
Hims & Hers Health, Inc. (HIMS) reachead $37.04 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and women's health, dermatology, and mental health, along with its personalized healthcare solutions, supports long-term growth potential. Strong financial performance with a 69% revenue increase in 2024, a growing subscriber base, and improved marketing efficiency highlight H&H's disciplined growth strategy.
Hims & Hers Health (HIMS) Moves 5.7% Higher: Will This Strength Last?
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Hims & Hers Health: Developing A Better Understanding
Hims & Hers Health has become one of the most popular growth stocks in the market today. After sharing with my readers a bullish perspective on the stock at ~$6/share in 2023, I'm back to provide a unique perspective that sheds light on what the platform does. In short, I like to call Hims an "AI-orchestrated general physician at national scale," and I'll walk us through what that means today.
Jumping Into The FDA Gamble: Initiating Hims & Hers With A Buy
Hims & Hers Health, Inc. stock surged to $68, and the subsequent 50% crash is the talk of the town. I'm eyeing it as a favorable high-risk, high-reward play. HIMS stock plummeted after the FDA halted approval of its top-selling GLP-1 weight loss drug, which is priced at $165 and offers the same as Ozempic, priced on average $1,000. The FDA's pending decision on semaglutide's shortage status, due April 22nd, is crucial; a favorable ruling could boost HIMS stock significantly.
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Hims & Hers (HIMS) is a newfangled tele-health company that started to ride the waves of GLP-1 weight loss medications. As waves go, this one's given the stock a heck of ride; way up and then all the way back down. More big moves could happen in the near term. Looking deeper and reading a lot of tea leaves, I envision HIMS growing from a peddler of feel-good non-essential medications into a serious player in the emerging personalized medicine field.
